Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. We conducted a single arm phase II and biomarker study that enrolled pat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Tolaney, Sara M., Ziehr, David R., Guo, Hao, Ng, Mei R., Barry, William T., Higgins, Michaela J., Isakoff, Steven J., Brock, Jane E., Ivanova, Elena V., Paweletz, Cloud P., Demeo, Michelle K., Ramaiya, Nikhil H., Overmoyer, Beth A., Jain, Rakesh K., Winer, Eric P., Duda, Dan G.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Breast Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313267/
https://ncbi.nlm.nih.gov/pubmed/27789775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0229
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki